{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T21:24:49Z","timestamp":1774128289742,"version":"3.50.1"},"reference-count":88,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDDT"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>A persistent long-standing, inflammatory skin condition that is brought on by a variety\nof factors is psoriasis. It is distinguished by itchy, scaly, reddish plaques, particularly on areas of\nthe body that are frequently chafed, including the extensor sites of the limbs. Recent developments\nin molecular-targeted therapy that use biologics or small-molecule inhibitors can effectively\ncure even the worst psoriatic indications. The outstanding clinical outcomes of treatment help to\nclarify the disease's detrimental consequences on quality of life. Biomarkers that identify deep remission\nare essential for developing uniform treatment plans. Blood protein markers such as\nAMPs that are consistently quantifiable can be very helpful in routine clinical practice. The\nmetabolic pathways involve biomarkers that can not only help diagnose psoriasis in a clinical setting\nbut also indicate its severity based on the levels present in the body. Machine learning and AI\nhave made a diagnosis of the expression of genes as biomarkers more accessible. In this article,\nbiomarkers, as well as their key role in psoriasis, are discussed<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115701638278470240312075112","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T05:37:12Z","timestamp":1710826632000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Snapshot of Biomarkers in Psoriasis"],"prefix":"10.2174","volume":"22","author":[{"given":"Krushna","family":"Abhale","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Addepalli","family":"Veeranjaneyulu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Dr. D. Y. Patil Vidyapeeth, Pimpri, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani","family":"Desai","sequence":"additional","affiliation":[{"name":"Clinical Research and Pharmacovigilance,\nSerum Institute of India Pvt. Ltd., Hadapsar, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"157","author":"Armstrong A.W.","year":"2021","unstructured":"Armstrong A.W.; Mehta M.D.; Schupp C.W.; Gondo G.C.; Bell S.J.; Griffiths C.E.M.; Psoriasis prevalence in adults in the United States. JAMA Dermatol  2021,157(8),940-946","journal-title":"JAMA Dermatol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"Mease P.J.","year":"2013","unstructured":"Mease P.J.; Gladman D.D.; Papp K.A.; Khraishi M.M.; Tha\u00e7i D.; Behrens F.; Northington R.; Fuiman J.; Bananis E.; Boggs R.; Alvarez D.; Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol  2013,69(5),729-735","journal-title":"J Am Acad Dermatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"Griffiths C.E.M.","year":"2007","unstructured":"Griffiths C.E.M.; Barker J.N.W.N.; Pathogenesis and clinical features of psoriasis. Lancet  2007,370(9583),263-271","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/PTT.S169389","volume":"8","author":"Yang E.","year":"2018","unstructured":"Yang E.; Beck K.; Sanchez I.; Koo J.; Liao W.; The impact of genital psoriasis on quality of life: A systematic review. Psoriasis Targets Ther  2018,8,41-47","journal-title":"Psoriasis Targets Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3389\/fimmu.2018.01668","volume":"9","author":"Caiazzo G.","year":"2018","unstructured":"Caiazzo G.; Fabbrocini G.; Di Caprio R.; Raimondo A.; Scala E.; Balato N.; Balato A.; Psoriasis, cardiovascular events, and biologics: Lights and shadows. Front Immunol  2018,9,1668","journal-title":"Front Immunol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","volume":"20","author":"Boehncke W.H.","year":"2011","unstructured":"Boehncke W.H.; Boehncke S.; Tobin A.M.; Kirby B.; The \u2018psoriatic march\u2019: A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol  2011,20(4),303-307","journal-title":"Exp Dermatol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.36660\/ijcs.20200021","volume":"33","author":"Boechat J.L.","year":"2020","unstructured":"Boechat J.L.; Psoriatic march, skin inflammation and cardiovascular events \u2013 two plaques for one syndrome. Int J Cardiovasc Sci  2020,33(2),109-111","journal-title":"Int J Cardiovasc Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3389\/fimmu.2018.01210","volume":"9","author":"Tang L.","year":"2018","unstructured":"Tang L.; Yang X.; Liang Y.; Xie H.; Dai Z.; Zheng G.; Transcription factor retinoid-related orphan receptor \u03b3t: A promising target for the treatment of psoriasis. Front Immunol  2018,9,1210","journal-title":"Front Immunol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.it.2008.12.003","volume":"30","author":"Lai Y.","year":"2009","unstructured":"Lai Y.; Gallo R.L.; AMPed up immunity: How antimicrobial peptides have multiple roles in immune defense. Trends Immunol  2009,30(3),131-141","journal-title":"Trends Immunol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/1346-8138.14139","volume":"45","author":"Ogawa E.","year":"2018","unstructured":"Ogawa E.; Sato Y.; Minagawa A.; Okuyama R.; Pathogenesis of psoriasis and development of treatment. J Dermatol  2018,45(3),264-272","journal-title":"J Dermatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1346-8138.2011.01483.x","volume":"39","author":"Morizane S.","year":"2012","unstructured":"Morizane S.; Gallo R.L.; Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol  2012,39(3),225-230","journal-title":"J Dermatol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.3390\/ijms21186791","volume":"21","author":"Takahashi T.","year":"2020","unstructured":"Takahashi T.; Yamasaki K.; Psoriasis and antimicrobial peptides. Int J Mol Sci  2020,21(18),6791","journal-title":"Int J Mol Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1084\/jem.20151093","volume":"212","author":"Arakawa A.","year":"2015","unstructured":"Arakawa A.; Siewert K.; St\u00f6hr J.; Besgen P.; Kim S.M.; R\u00fchl G.; Nickel J.; Vollmer S.; Thomas P.; Krebs S.; Pinkert S.; Spannagl M.; Held K.; Kammerbauer C.; Besch R.; Dornmair K.; Prinz J.C.; Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med  2015,212(13),2203-2212","journal-title":"J Exp Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.4049\/jimmunol.1300348","volume":"191","author":"Nishimoto S.","year":"2013","unstructured":"Nishimoto S.; Kotani H.; Tsuruta S.; Shimizu N.; Ito M.; Shichita T.; Morita R.; Takahashi H.; Amagai M.; Yoshimura A.; Th17 cells carrying TCR recognizing epidermal autoantigen induce psoriasis-like skin inflammation. J Immunol  2013,191(6),3065-3072","journal-title":"J Immunol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.5483\/BMBRep.2014.47.2.014","volume":"47","author":"Kim T.G.","year":"2014","unstructured":"Kim T.G.; Kim D.S.; Kim H.P.; Lee M.G.; The pathophysiological role of dendritic cell subsets in psoriasis. BMB Rep  2014,47(2),60-68","journal-title":"BMB Rep"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/1346-8138.15184","volume":"47","author":"Wang A.","year":"2020","unstructured":"Wang A.; Bai Y.; Dendritic cells: The driver of psoriasis. J Dermatol  2020,47(2),104-113","journal-title":"J Dermatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"24477","DOI":"10.1038\/srep24477","volume":"6","author":"Takagi H.","year":"2016","unstructured":"Takagi H.; Arimura K.; Uto T.; Fukaya T.; Nakamura T.; Choijookhuu N.; Hishikawa Y.; Sato K.; Plasmacytoid dendritic cells orchestrate TLR7-mediated innate and adaptive immunity for the initiation of autoimmune inflammation. Sci Rep  2016,6(1),24477","journal-title":"Sci Rep"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jid.2017.09.052","volume":"138","author":"Kopfnagel V.","year":"2018","unstructured":"Kopfnagel V.; Wagenknecht S.; Harder J.; Hofmann K.; Kleine M.; Buch A.; Sodeik B.; Werfel T.; RNase 7 strongly promotes TLR9-mediated DNA sensing by human plasmacytoid dendritic cells. J Invest Dermatol  2018,138(4),872-881","journal-title":"J Invest Dermatol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"596086","DOI":"10.3389\/fimmu.2020.596086","volume":"11","author":"Vecellio M.","year":"2021","unstructured":"Vecellio M.; Hake V.X.; Davidson C.; Carena M.C.; Wordsworth B.P.; Selmi C.; The IL-17\/IL-23 axis and its genetic contribution to psoriatic arthritis. Front Immunol  2021,11,596086","journal-title":"Front Immunol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","volume":"13","author":"Suzuki E.","year":"2014","unstructured":"Suzuki E.; Mellins E.D.; Gershwin M.E.; Nestle F.O.; Adamopoulos I.E.; The IL-23\/IL-17 axis in psoriatic arthritis. Autoimmun Rev  2014,13(4-5),496-502","journal-title":"Autoimmun Rev"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1002\/msc.1694","volume":"20","author":"Fragoulis G.E.","year":"2022","unstructured":"Fragoulis G.E.; Siebert S.; The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. Musculoskelet Care  2022,20(S1),S12-S21","journal-title":"Musculoskelet Care"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","volume":"27","author":"Korn T.","year":"2009","unstructured":"Korn T.; Bettelli E.; Oukka M.; Kuchroo V.K.; IL-17 and Th17 cells. Annu Rev Immunol  2009,27(1),485-517","journal-title":"Annu Rev Immunol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-med-042915-103905","volume":"68","author":"Kim J.","year":"2017","unstructured":"Kim J.; Krueger J.G.; Highly effective new treatments for psoriasis target the IL-23\/type 17 T cell autoimmune axis. Annu Rev Med  2017,68(1),255-269","journal-title":"Annu Rev Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","volume":"140","author":"Hawkes J.E.","year":"2017","unstructured":"Hawkes J.E.; Chan T.C.; Krueger J.G.; Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol  2017,140(3),645-653","journal-title":"J Allergy Clin Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/jid.2009.65","volume":"129","author":"Harper E.G.","year":"2009","unstructured":"Harper E.G.; Guo C.; Rizzo H.; Lillis J.V.; Kurtz S.E.; Skorcheva I.; Purdy D.; Fitch E.; Iordanov M.; Blauvelt A.; Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: Implications for psoriasis pathogenesis. J Invest Dermatol  2009,129(9),2175-2183","journal-title":"J Invest Dermatol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1365-2613.2009.00669.x","volume":"90","author":"Heidenreich R.","year":"2009","unstructured":"Heidenreich R.; R\u00f6cken M.; Ghoreschi K.; Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol  2009,90(3),232-248","journal-title":"Int J Exp Pathol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.3390\/ijms21062195","volume":"21","author":"Kim H.R.","year":"2020","unstructured":"Kim H.R.; Kang S.Y.; Kim H.O.; Park C.W.; Chung B.Y.; Role of aryl hydrocarbon receptor activation and autophagy in psoriasis-related inflammation. Int J Mol Sci  2020,21(6),2195","journal-title":"Int J Mol Sci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev.pharmtox.43.100901.135828","volume":"43","author":"Denison M.S.","year":"2003","unstructured":"Denison M.S.; Nagy S.R.; Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol  2003,43(1),309-334","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1146\/annurev-immunol-032713-120245","volume":"32","author":"Stockinger B.","year":"2014","unstructured":"Stockinger B.; Meglio P.D.; Gialitakis M.; Duarte J.H.; The aryl hydrocarbon receptor: Multitasking in the immune system. Annu Rev Immunol  2014,32(1),403-432","journal-title":"Annu Rev Immunol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.3390\/ijms20215424","volume":"20","author":"Furue M.","year":"2019","unstructured":"Furue M.; Hachiya H.A.; Tsuji G.; Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci  2019,20(21),5424","journal-title":"Int J Mol Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jid.2019.11.022","volume":"140","author":"Zhu Z.","year":"2020","unstructured":"Zhu Z.; Chen J.; Lin Y.; Zhang C.; Li W.; Qiao H.; Fu M.; Dang E.; Wang G.; Aryl hydrocarbon receptor in cutaneous vascular endothelial cells restricts psoriasis development by negatively regulating neutrophil recruitment. J Invest Dermatol  2020,140(6),1233-1243.e9","journal-title":"J Invest Dermatol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"23.1","DOI":"10.1002\/cpph.19","volume":"76","author":"Aronson J.K.","year":"2017","unstructured":"Aronson J.K.; Ferner R.E.; Biomarkers\u2014A general review. Curr Protocols Pharmacol  2017,76(1),23.1-, 17","journal-title":"Curr Protocols Pharmacol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00403-012-1229-1","volume":"304","author":"Yilmaz S.B.","year":"2012","unstructured":"Yilmaz S.B.; Cicek N.; Coskun M.; Yegin O.; Alpsoy E.; Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res  2012,304(6),465-469","journal-title":"Arch Dermatol Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","volume":"139","author":"Kolbinger F.","year":"2017","unstructured":"Kolbinger F.; Loesche C.; Valentin M.A.; Jiang X.; Cheng Y.; Jarvis P.; Peters T.; Calonder C.; Bruin G.; Polus F.; Aigner B.; Lee D.M.; Bodenlenz M.; Sinner F.; Pieber T.R.; Patel D.D.; \u03b2-Defensin 2 is a responsive biomarker of IL-17A\u2013driven skin pathology in patients with psoriasis. J Allergy Clin Immunol  2017,139(3),923-932.e8","journal-title":"J Allergy Clin Immunol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","volume":"139","author":"Gordon K.B.","year":"2019","unstructured":"Gordon K.B.; Armstrong A.W.; Foley P.; Song M.; Shen Y.K.; Li S.; Mu\u00f1oz-El\u00edas E.J.; Branigan P.; Liu X.; Reich K.; Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study. J Invest Dermatol  2019,139(12),2437-2446.e1","journal-title":"J Invest Dermatol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1038\/s41598-019-41609-z","volume":"9","author":"Konrad R.J.","year":"2019","unstructured":"Konrad R.J.; Higgs R.E.; Rodgers G.H.; Ming W.; Qian Y.W.; Bivi N.; Mack J.K.; Siegel R.W.; Nickoloff B.J.; Assessment and clinical relevance of serum IL-19 levels in psoriasis and atopic dermatitis using a sensitive and specific novel immunoassay. Sci Rep  2019,9(1),5211","journal-title":"Sci Rep"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jdermsci.2011.11.011","volume":"65","author":"Honma M.","year":"2012","unstructured":"Honma M.; Minami-Hori M.; Takahashi H.; Iizuka H.; Podoplanin expression in wound and hyperproliferative psoriatic epidermis: Regulation by TGF-\u03b2 and STAT-3 activating cytokines, IFN-\u03b3, IL-6, and IL-22. J Dermatol Sci  2012,65(2),134-140","journal-title":"J Dermatol Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","volume":"48","author":"Yassky G.E.","year":"2017","unstructured":"Yassky G.E.; Krueger J.G.; Atopic dermatitis and psoriasis: Two different immune diseases or one spectrum? Curr Opin Immunol  2017,48,68-73","journal-title":"Curr Opin Immunol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/1346-8138.12248","volume":"40","author":"Shimauchi T.","year":"2013","unstructured":"Shimauchi T.; Hirakawa S.; Suzuki T.; Yasuma A.; Majima Y.; Tatsuno K.; Yagi H.; Ito T.; Tokura Y.; Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis. J Dermatol  2013,40(10),805-812","journal-title":"J Dermatol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/nyas.13280","volume":"1417","author":"Walsh P.T.","year":"2018","unstructured":"Walsh P.T.; Fallon P.G.; The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases. Ann N Y Acad Sci  2018,1417(1),23-34","journal-title":"Ann N Y Acad Sci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2340\/00015555-2808","volume":"98","author":"Furue K.","year":"2018","unstructured":"Furue K.; Yamamura K.; Tsuji G.; Mitoma C.; Uchi H.; Nakahara T.; Nakahara K.M.; Kadono T.; Furue M.; Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol  2018,98(1),5-13","journal-title":"Acta Derm Venereol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3389\/fimmu.2019.01162","volume":"10","author":"Buhl A.L.","year":"2019","unstructured":"Buhl A.L.; Wenzel J.; Interleukin-36 in infectious and inflammatory skin diseases. Front Immunol  2019,10,1162","journal-title":"Front Immunol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.3390\/ijms20133318","volume":"20","author":"Madonna S.","year":"2019","unstructured":"Madonna S.; Girolomoni G.; Dinarello C.A.; Albanesi C.; The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis. Int J Mol Sci  2019,20(13),3318","journal-title":"Int J Mol Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/jid.2014.532","volume":"135","author":"D\u2019Erme A.M.","year":"2015","unstructured":"D\u2019Erme A.M.; Wilsmann-Theis D.; Wagenpfeil J.; H\u00f6lzel M.; Schmitt F.S.; Sternberg S.; Wittmann M.; Peters B.; Bosio A.; Bieber T.; Wenzel J.; IL-36\u03b3 (IL-1F9) is a biomarker for psoriasis skin lesions. J Invest Dermatol  2015,135(4),1025-1032","journal-title":"J Invest Dermatol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2340\/00015555-2265","volume":"96","author":"Braegelmann J.","year":"2016","unstructured":"Braegelmann J.; D\u00b4Erme A.; Akmal S.; Maier J.; Braegelmann C.; Wenzel J.; Interleukin-36\u03b3 (IL-1F9) identifies psoriasis among patients with erythroderma. Acta Derm Venereol  2016,96(3),386-387","journal-title":"Acta Derm Venereol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1046\/j.1365-2133.2001.04219.x","volume":"144","author":"Raychaudhuri S.P.","year":"2001","unstructured":"Raychaudhuri S.P.; Jiang W-Y.; Farber E.M.; Cellular localization of fractalkine at sites of inflammation: antigen-presenting cells in psoriasis express high levels of fractalkine. Br J Dermatol  2001,144(6),1105-1113","journal-title":"Br J Dermatol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1172\/JCI11517","volume":"107","author":"Fraticelli P.","year":"2001","unstructured":"Fraticelli P.; Sironi M.; Bianchi G.; D\u2019Ambrosio D.; Albanesi C.; Stoppacciaro A.; Chieppa M.; Allavena P.; Ruco L.; Girolomoni G.; Sinigaglia F.; Vecchi A.; Mantovani A.; Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest  2001,107(9),1173-1181","journal-title":"J Clin Invest"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0923-1811(03)00031-8","volume":"31","author":"Sugaya M.","year":"2003","unstructured":"Sugaya M.; Nakamura K.; Mitsui H.; Takekoshi T.; Saeki H.; Tamaki K.; Human keratinocytes express fractalkine\/CX3CL1. J Dermatol Sci  2003,31(3),179-187","journal-title":"J Dermatol Sci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1517\/14728222.2010.504716","volume":"14","author":"Hedrick M.N.","year":"2010","unstructured":"Hedrick M.N.; Lonsdorf A.S.; Hwang S.T.; Farber J.M.; CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets  2010,14(9),911-922","journal-title":"Expert Opin Ther Targets"},{"key":"ref=50","first-page":"556","volume":"45","author":"Congjun J.","year":"2015","unstructured":"Congjun J.; Yanmei Z.; Huiling J.; Zhen Y.; Shuo L.; Elevated local and serum CX3CL1(Fractalkine) expression and its association with disease severity in patients with psoriasis. Ann Clin Lab Sci  2015,45(5),556-561","journal-title":"Ann Clin Lab Sci"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2004.02.030","volume":"113","author":"Echigo T.","year":"2004","unstructured":"Echigo T.; Hasegawa M.; Shimada Y.; Takehara K.; Sato S.; Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: Possible contribution to skin inflammation. J Allergy Clin Immunol  2004,113(5),940-948","journal-title":"J Allergy Clin Immunol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1111\/febs.14466","volume":"285","author":"Hughes C.E.","year":"2018","unstructured":"Hughes C.E.; Nibbs R.J.B.; A guide to chemokines and their receptors. FEBS J  2018,285(16),2944-2971","journal-title":"FEBS J"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/labinvest.3780242","volume":"81","author":"Rottman J.B.","year":"2001","unstructured":"Rottman J.B.; Smith T.L.; Ganley K.G.; Kikuchi T.; Krueger J.G.; Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest  2001,81(3),335-347","journal-title":"Lab Invest"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/1346-8138.14308","volume":"45","author":"Shibuya T.","year":"2018","unstructured":"Shibuya T.; Honma M.; Iinuma S.; Iwasaki T.; Takahashi H.; Yamamoto I.A.; Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents. J Dermatol  2018,45(6),710-714","journal-title":"J Dermatol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3390\/cancers13040884","volume":"13","author":"Zijtregtop E.A.M.","year":"2021","unstructured":"Zijtregtop E.A.M.; van der Strate I.; Beishuizen A.; Zwaan C.M.; Vermeulen H.M.A.; Brandsma A.M.; Wentrup M.F.; Biology and clinical applicability of plasma thymus and activation-regulated chemokine (TARC) in classical hodgkin lymphoma. Cancers  2021,13(4),884","journal-title":"Cancers"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri2921","volume":"11","author":"Ouchi N.","year":"2011","unstructured":"Ouchi N.; Parker J.L.; Lugus J.J.; Walsh K.; Adipokines in inflammation and metabolic disease. Nat Rev Immunol  2011,11(2),85-97","journal-title":"Nat Rev Immunol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1111\/jdv.13701","volume":"30","author":"Coimbra S","year":"2016","unstructured":"Coimbra S; Catarino C.; Silva A.S.; The triad psoriasis-obesity-adipokine profile. J Eur Acad Dermatol Venereol  2016,30(11),1876-1885","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3389\/fimmu.2019.01507","volume":"10","author":"Wong Y.","year":"2019","unstructured":"Wong Y.; Nakamizo S.; Tan K.J.; Kabashima K.; An update on the role of adipose tissues in psoriasis. Front Immunol  2019,10,1507","journal-title":"Front Immunol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","volume":"13","author":"Versini M.","year":"2014","unstructured":"Versini M.; Jeandel P.Y.; Rosenthal E.; Shoenfeld Y.; Obesity in autoimmune diseases: Not a passive bystander. Autoimmun Rev  2014,13(9),981-1000","journal-title":"Autoimmun Rev"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00403-012-1310-9","volume":"305","author":"Takahashi H.","year":"2013","unstructured":"Takahashi H.; Tsuji H.; Honma M.; Yamamoto I.A.; Iizuka H.; Increased plasma resistin and decreased omentin levels in Japanese patients with psoriasis. Arch Dermatol Res  2013,305(2),113-116","journal-title":"Arch Dermatol Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.16437","volume":"179","author":"Kyriakou A.","year":"2018","unstructured":"Kyriakou A.; Patsatsi A.; Sotiriadis D.; Goulis D.G.; Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: A systematic review and meta-analysis. Br J Dermatol  2018,179(2),273-281","journal-title":"Br J Dermatol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.18632\/oncotarget.22260","volume":"9","author":"Bai F.","year":"2018","unstructured":"Bai F.; Zheng W.; Dong Y.; Wang J.; Garstka M.A.; Li R.; An J.; Ma H.; Serum levels of adipokines and cytokines in psoriasis patients: A systematic review and meta-analysis. Oncotarget  2018,9(1),1266-1278","journal-title":"Oncotarget"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/j.1468-3083.2010.03647.x","volume":"24","author":"Coimbra S.","year":"2010","unstructured":"Coimbra S.; Oliveira H.; Reis F.; Belo L.; Rocha S.; Quintanilha A.; Figueiredo A.; Teixeira F.; Castro E.; Rocha-Pereira P.; Santos-Silva A.; Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol  2010,24(12),1386-1394","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/j.1468-3083.2010.03947.x","volume":"25","author":"Boehncke S.","year":"2011","unstructured":"Boehncke S.; Salgo R.; Garbaraviciene J.; Beschmann H.; Hardt K.; Diehl S.; Fichtlscherer S.; Tha\u00e7i D.; Boehncke W.H.; Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: Results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol  2011,25(10),1187-1193","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/09546634.2019.1621979","volume":"31","author":"Gerdes S.","year":"2020","unstructured":"Gerdes S.; Pinter A.; Biermann M.; Papavassilis C.; Reinhardt M.; Adiponectin levels in a large pooled plaque psoriasis study population. J Dermatolog Treat  2020,31(5),531-534","journal-title":"J Dermatolog Treat"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1046\/j.0022-202x.2001.01401.x","volume":"117","author":"Falconer A.","year":"2001","unstructured":"Falconer A.; Ikram M.; Bissett C.E.; Cerio R.; Quinn A.G.; Ali R.S.; Expression of the peptide antibiotics human \u03b2 defensin-1 and human \u03b2 defensin-2 in normal human skin. J Invest Dermatol  2001,117(1),106-111","journal-title":"J Invest Dermatol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/jid.2010.340","volume":"131","author":"Chiricozzi A.","year":"2011","unstructured":"Chiricozzi A.; Yassky G.E.; Fari\u00f1as S.M.; Nograles K.E.; Tian S.; Cardinale I.; Chimenti S.; Krueger J.G.; Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol  2011,131(3),677-687","journal-title":"J Invest Dermatol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"118677","DOI":"10.1016\/j.bbamcr.2020.118677","volume":"1867","author":"Gonzalez L.L.","year":"2020","unstructured":"Gonzalez L.L.; Garrie K.; Turner M.D.; Role of S100 proteins in health and disease. Biochim Biophys Acta Mol Cell Res  2020,1867(6),118677","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.clindermatol.2007.08.016","volume":"25","author":"B\u00fcchau A.S.","year":"2007","unstructured":"B\u00fcchau A.S.; Gallo R.L.; Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol  2007,25(6),616-624","journal-title":"Clin Dermatol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cytogfr.2016.01.002","volume":"32","author":"D\u2019Amico F.","year":"2016","unstructured":"D\u2019Amico F.; Skarmoutsou E.; Granata M.; Trovato C.; Rossi G.A.; Mazzarino M.C.; S100A7: A rAMPing up AMP molecule in psoriasis. Cytokine Growth Factor Rev  2016,32,97-104","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1111\/bjd.18807","volume":"182","author":"Maurelli M.","year":"2020","unstructured":"Maurelli M.; Gisondi P.; Danese E.; Gelati M.; Papagrigoraki A.; Giglio M.; Lippi G.; Girolomoni G.; Psoriasin (S100A7) is increased in the serum of patients with moderate-to-severe psoriasis. Br J Dermatol  2020,182(6),1502-1503","journal-title":"Br J Dermatol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1111\/bjd.14426","volume":"174","author":"Watanabe Y.","year":"2016","unstructured":"Watanabe Y.; Yamaguchi Y.; Komitsu N.; Ohta S.; Azuma Y.; Izuhara K.; Aihara M.; Elevation of serum squamous cell carcinoma antigen 2 in patients with psoriasis: associations with disease severity and response to the treatment. Br J Dermatol  2016,174(6),1327-1336","journal-title":"Br J Dermatol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1346-8138.2004.tb00672.x","volume":"31","author":"Iizuka H.","year":"2004","unstructured":"Iizuka H.; Takahashi H.; Honma M.; Yamamoto I.A.; Unique keratinization process in psoriasis: Late differentiation markers are abolished because of the premature cell death. J Dermatol  2004,31(4),271-276","journal-title":"J Dermatol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1046\/j.1523-1747.2002.01803.x","volume":"119","author":"Nakane H.","year":"2002","unstructured":"Nakane H.; Ishida-Yamamoto A.; Takahashi H.; Iizuka H.; Elafin, a secretory protein, is cross-linked into the cornified cell envelopes from the inside of psoriatic keratinocytes. J Invest Dermatol  2002,119(1),50-55","journal-title":"J Invest Dermatol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/1523-1747.ep12391802","volume":"103","author":"Nonomura K.","year":"1994","unstructured":"Nonomura K.; Yamanishi K.; Yasuno H.; Nara K.; Hirose S.; Up-regulation of elafin\/SKALP gene expression in psoriatic epidermis. J Invest Dermatol  1994,103(1),88-91","journal-title":"J Invest Dermatol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1165\/rcmb.2010-0095RT","volume":"42","author":"Sallenave J.M.","year":"2010","unstructured":"Sallenave J.M.; Secretory leukocyte protease inhibitor and elafin\/trappin-2: versatile mucosal antimicrobials and regulators of immunity. Am J Respir Cell Mol Biol  2010,42(6),635-643","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2340\/0001555577014019","volume":"77","author":"Kuijpers A.L.","year":"1997","unstructured":"Kuijpers A.L.; Bergers M.; Siegenthaler G.; Zeeuwen P.L.; Van de Kerkhof P.C.; Schalkwijk J.; Skin-derived antileukoproteinase (SKALP) and epidermal fatty acid-binding protein (E-FABP): Two novel markers of the psoriatic phenotype that respond differentially to topical steroid. Acta Derm Venereol  1997,77(1),14-19","journal-title":"Acta Derm Venereol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/1523-1747.ep12616641","volume":"99","author":"Madsen P.","year":"1992","unstructured":"Madsen P.; Rasmussen H.H.; Leffers H.; Honor\u00e9 B.; Celis J.E.; Molecular cloning and expression of a novel keratinocyte protein (psoriasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins. J Invest Dermatol  1992,99(3),299-305","journal-title":"J Invest Dermatol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/jid.2010.342","volume":"131","author":"Ogawa E.","year":"2011","unstructured":"Ogawa E.; Owada Y.; Ikawa S.; Adachi Y.; Egawa T.; Nemoto K.; Suzuki K.; Hishinuma T.; Kawashima H.; Kondo H.; Muto M.; Aiba S.; Okuyama R.; Epidermal FABP (FABP5) regulates keratinocyte differentiation by 13(S)-HODE-mediated activation of the NF-\u03baB signaling pathway. J Invest Dermatol  2011,131(3),604-612","journal-title":"J Invest Dermatol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jdermsci.2017.01.008","volume":"86","author":"Nakajima H.","year":"2017","unstructured":"Nakajima H.; Serada S.; Fujimoto M.; Naka T.; Sano S.; Leucine-rich \u03b1-2 glycoprotein is an innovative biomarker for psoriasis. J Dermatol Sci  2017,86(2),170-174","journal-title":"J Dermatol Sci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cca.2020.09.035","volume":"511","author":"Deng Y.","year":"2020","unstructured":"Deng Y.; Li G.; Chang D.; Su X.; YKL-40 as a novel biomarker in cardio-metabolic disorders and inflammatory diseases. Clin Chim Acta  2020,511,40-46","journal-title":"Clin Chim Acta"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12916-016-0681-8","volume":"14","author":"Alonso A.","year":"2016","unstructured":"Alonso A.; Juli\u00e0 A.; Vinaixa M.; Dom\u00e8nech E.; Nebro F.A.; Ca\u00f1ete J.D.; Ferr\u00e1ndiz C.; Tornero J.; Gisbert J.P.; Nos P.; Casbas A.G.; Puig L.; \u00c1lvaro G.I.; Tasende P.J.A.; Blanco R.; Rodr\u00edguez M.A.; Beltran A.; Correig X.; Marsal S.; Urine metabolome profiling of immune-mediated inflammatory diseases. BMC Med  2016,14(1),133","journal-title":"BMC Med"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00403-017-1748-x","volume":"309","author":"My\u015bliwiec H.","year":"2017","unstructured":"My\u015bliwiec H.; Baran A.; Harasim-Symbor E.; My\u015bliwiec P.; Milewska A.J.; Chabowski A.; Flisiak I.; Serum fatty acid profile in psoriasis and its comorbidity. Arch Dermatol Res  2017,309(5),371-380","journal-title":"Arch Dermatol Res"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"739514","DOI":"10.3389\/fimmu.2021.739514","volume":"12","author":"Yu N.","year":"2021","unstructured":"Yu N.; Peng C.; Chen W.; Sun Z.; Zheng J.; Zhang S.; Ding Y.; Shi Y.; Circulating metabolomic signature in generalized pustular psoriasis blunts monocyte hyperinflammation by triggering amino acid response. Front Immunol  2021,12,739514","journal-title":"Front Immunol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/1346-8138.14933","volume":"46","author":"Shapiro J.","year":"2019","unstructured":"Shapiro J.; Cohen N.A.; Shalev V.; Uzan A.; Koren O.; Maharshak N.; Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls. J Dermatol  2019,46(7),595-603","journal-title":"J Dermatol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"100001","DOI":"10.1016\/j.meomic.2020.100001","volume":"1","author":"Le N.Q.K.","year":"2021","unstructured":"Le N.Q.K.; Do D.T.; Nguyen T.T.D.; Nguyen N.T.K.; Hung T.N.K.; Trang N.T.T.; Identification of gene expression signatures for psoriasis classification using machine learning techniques. Medicine in Omics  2021,1,100001","journal-title":"Medicine in Omics"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.2147\/IJGM.S441262","volume":"16","author":"Yao P.","year":"2023","unstructured":"Yao P.; Jia Y.; Kan X.; Chen J.; Xu J.; Xu H.; Shao S.; Ni B.; Tang J.; Identification of ADAM23 as a potential signature for psoriasis using integrative machine-learning and experimental verification. Int J Gen Med  2023,16,6051-6064","journal-title":"Int J Gen Med"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"e14606","DOI":"10.1111\/dth.14606","volume":"34","author":"Khashaba S.A.","year":"2021","unstructured":"Khashaba S.A.; Attwa E.; Said N.; Ahmed S.; Khattab F.; Serum -40 and  17 in psoriasis: Reliability as prognostic markers for disease severity and responsiveness to treatment. Dermatol Ther  2021,34(1),e14606","journal-title":"Dermatol Ther"}],"container-title":["Current Drug Discovery Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701638278470240312075112","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/228068\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701638278470240312075112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T08:51:22Z","timestamp":1730278282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/228068\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115701638278470240312075112","relation":{},"ISSN":["1570-1638"],"issn-type":[{"value":"1570-1638","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-09-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e180324228068"}}